Aspira Women's Health Inc expected to post a loss of 45 cents a share - Earnings Preview

Aspira Women's Health

26/03/2024 13:29

* Aspira Women's Health Inc  AWH.OQ   AWH.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 28
for the period ending December 31 2023
    * The Austin Texas-based  company is expected to report a
18.2% increase in revenue to $2.545 million from $2.15 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Aspira Women's Health
Inc is
for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aspira
Women's
Health Inc is $5.60​, above​ its last closing price of $3.56.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.45       -0.51      -0.48     Beat    5.4
 Jun. 30 2023  -0.55       -0.55      -0.28     Beat    49.1
 Mar. 31 2023  -0.75       -0.75      -0.73     Beat    2.7​
 Dec. 31 2022  -1.05       -0.97      -0.60     Beat    38.5
 ​​Sep.        -0.98       -0.97      -1.20     Missed  -23.1
 30 2022                                                
 Jun. 30 2022  -1.05       -1.05      -1.05     Met     0​
 Mar. 31 2022  -1.20       -1.20      -1.20     Met     0
 Dec. 31 2021  -1.18       -1.20      -1.20     Met     0
 This summary was machine generated March 26 at 13:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)